Organogenix - About the company
Organogenix is a deadpooled company based in Kawasaki (Japan), founded in 2013. It operates as a Matrix free, scaffold based 3D cell culture products. The company has 1955 active competitors, including 454 funded and 337 that have exited. Its top competitors include companies like Sutro Biopharma, Synthego and Avidity Biosciences.
Company Details
Organogenix (formerly known as SciVax), a subsidiary of JSR Corporation manufactures matrix free, scaffold-based 3D cell culture products. It offers, NanoCulturePlate (NCP), as its core product (cell culture system) for spheroid growth. The 3D patterned nanostructure design of the NCP NanoCulture Plate and NanoCulture Dish are used for multiple applications including cancer research, drug discovery, hepatotoxicity study and stem cell research.
Key Metrics
Founded Year
2013
Location
Kawasaki, Japan
Stage
Deadpooled
Ranked
2541st among 2670 competitors
Similar Companies
Sign up to download Organogenix's company profile
Organogenix's funding and investors
Organogenix has not raised any funding rounds yet.
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Organogenix's Competitors and alternates
Top competitors of Organogenix include Sutro Biopharma, Synthego and Avidity Biosciences. Here is the list of Top 10 competitors of Organogenix, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
2nd | Synthego 2012, Redwood City (United States), Acquired | Developer of CRISPR-engineered cell and gene therapies | $460M | 71/100 | |
3rd |  Avidity Biosciences 2012, San Diego (United States), Acquired | RNA therapeutics innovator targeting muscle and other diseases with AOC platform | $143M | 70/100 | |
4th | Antheia 2013, Palo Alto (United States), Series C | Genetically engineered yeast cells to produce medicinal products | $176M | 67/100 | |
5th | Transcenta 2019, Suzhou (China), Public | Developer of antibody-based therapeutics | $205M | 66/100 | |
6th | Developer of antibody drug conjugates for the treatment of broad spectrum diseases | $195M | 65/100 | ||
7th | Korro Bio 2018, Cambridge (United States), Public | Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases | $4M | 64/100 | |
8th | Life Biosciences 2017, Boston (United States), Series D | Biotechnology pioneering cellular rejuvenation therapies to reverse and prevent aging diseases | $261M | 64/100 | |
9th | Fermentalg 2005, Libourne (France), Public | Innovating with algae for sustainable solutions in nutrition and environmental impact | $30.3M | 63/100 | |
10th | Microban 1994, Huntersville (United States), Acquired | Antimicrobial and odor control technologies for durable product protection and freshness | $64.6M | 63/100 | |
2541st | Organogenix 2013, Kawasaki (Japan), Deadpooled | Matrix free, scaffold based 3D cell culture products | - | - | 15/100 |
_1523881431192.png?devicePixelRatio=2&height=30&width=30){kind=logo}
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Organogenix's competitors? Click here to see the top ones
Organogenix's Investments and acquisitions
Organogenix has made no investments or acquisitions yet.
Are you a Founder ?
FAQs about Organogenix
Explore our recently published companies
- Rebellion-Timepieces - 2007 founded, Unfunded company
- Silvretta - 1990 founded, Unfunded company
- Sport-Resort - Unfunded company
- Strong Network - Lausanne based, 2020 founded, Unfunded company
- Anglo International Shipping - London based, 2017 founded, Seed company
- SciAstra - Noida based, 2021 founded, Unfunded company
